# A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

> **NCT02671955** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 12 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** JNJ-61610588

## Key facts

- **NCT ID:** NCT02671955
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-07
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Janssen business decision
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671955, "A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02671955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*